Annual Income Statements for Eupraxia Pharmaceuticals
This table shows Eupraxia Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.
Quarterly Income Statements for Eupraxia Pharmaceuticals
No quarterly income statements for Eupraxia Pharmaceuticals are available.
Annual Cash Flow Statements for Eupraxia Pharmaceuticals
This table details how cash moves in and out of Eupraxia Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.
| Metric |
2023 |
2024 |
2025 |
| Net Change in Cash & Equivalents |
0.26 |
16 |
47 |
| Net Cash From Operating Activities |
-21 |
-30 |
-29 |
| Net Cash From Continuing Operating Activities |
-21 |
-30 |
-29 |
| Net Income / (Loss) Continuing Operations |
-29 |
-26 |
-39 |
| Consolidated Net Income / (Loss) |
-29 |
-26 |
-39 |
| Depreciation Expense |
0.16 |
0.17 |
0.24 |
| Non-Cash Adjustments To Reconcile Net Income |
7.71 |
-2.66 |
10 |
| Changes in Operating Assets and Liabilities, net |
0.35 |
-1.76 |
-0.71 |
| Net Cash From Investing Activities |
-0.07 |
-0.08 |
-0.59 |
| Net Cash From Continuing Investing Activities |
-0.07 |
-0.08 |
-0.59 |
| Purchase of Property, Plant & Equipment |
-0.07 |
-0.10 |
-0.59 |
| Sale of Property, Plant & Equipment |
0.00 |
0.03 |
0.00 |
| Net Cash From Financing Activities |
21 |
46 |
76 |
| Net Cash From Continuing Financing Activities |
21 |
46 |
76 |
| Repayment of Debt |
-0.08 |
-9.14 |
0.00 |
| Issuance of Common Equity |
16 |
55 |
74 |
| Other Financing Activities, net |
5.27 |
0.36 |
2.17 |
Quarterly Cash Flow Statements for Eupraxia Pharmaceuticals
No quarterly cash flow statements for Eupraxia Pharmaceuticals are available.
Annual Balance Sheets for Eupraxia Pharmaceuticals
This table presents Eupraxia Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.
| Metric |
2023 |
2024 |
2025 |
| Total Assets |
20 |
35 |
86 |
| Total Current Assets |
20 |
34 |
85 |
| Cash & Equivalents |
19 |
33 |
81 |
| Note & Lease Receivable |
0.19 |
0.23 |
0.67 |
| Prepaid Expenses |
0.27 |
1.11 |
3.86 |
| Plant, Property, & Equipment, net |
0.41 |
0.36 |
0.83 |
| Total Noncurrent Assets |
0.05 |
0.15 |
0.22 |
| Other Noncurrent Operating Assets |
0.05 |
0.15 |
0.22 |
| Total Liabilities & Shareholders' Equity |
20 |
35 |
86 |
| Total Liabilities |
19 |
3.10 |
5.70 |
| Total Current Liabilities |
14 |
3.10 |
5.63 |
| Accounts Payable |
3.92 |
3.03 |
5.55 |
| Other Current Liabilities |
0.05 |
0.07 |
0.08 |
| Total Noncurrent Liabilities |
5.00 |
0.00 |
0.08 |
| Other Noncurrent Operating Liabilities |
5.00 |
0.00 |
0.08 |
| Total Equity & Noncontrolling Interests |
0.89 |
32 |
80 |
| Total Preferred & Common Equity |
2.22 |
33 |
82 |
| Total Common Equity |
2.22 |
33 |
82 |
| Common Stock |
110 |
137 |
224 |
| Retained Earnings |
-106 |
-131 |
-170 |
| Accumulated Other Comprehensive Income / (Loss) |
-2.71 |
-4.16 |
-2.04 |
| Other Equity Adjustments |
0.00 |
32 |
30 |
| Noncontrolling Interest |
-1.32 |
-1.57 |
-1.60 |
Quarterly Balance Sheets for Eupraxia Pharmaceuticals
No quarterly balance sheets for Eupraxia Pharmaceuticals are available.
Annual Metrics And Ratios for Eupraxia Pharmaceuticals
This table displays calculated financial ratios and metrics derived from Eupraxia Pharmaceuticals' official financial filings.
| Metric |
2023 |
2024 |
2025 |
| DEI Shares Outstanding |
0.00 |
- |
60,294,844.00 |
| DEI Adjusted Shares Outstanding |
0.00 |
- |
60,294,844.00 |
| DEI Earnings Per Adjusted Shares Outstanding |
0.00 |
- |
-0.64 |
| Growth Metrics |
- |
- |
- |
| Profitability Metrics |
- |
- |
- |
| Net Operating Profit after Tax (NOPAT) |
-19 |
-19 |
-27 |
| Return On Investment Capital (ROIC_SIMPLE) |
-172.64% |
-59.37% |
-33.44% |
| Earnings before Interest and Taxes (EBIT) |
-29 |
-26 |
-40 |
| Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) |
-28 |
-26 |
-40 |
| Valuation Ratios |
- |
- |
- |
| Leverage & Solvency |
- |
- |
- |
| Liquidity Ratios |
- |
- |
- |
| Cash Flow Metrics |
- |
- |
- |
| Free Cash Flow to Firm (FCFF) |
0.00 |
-26 |
-28 |
| Efficiency Ratios |
- |
- |
- |
| Capital & Investment Metrics |
- |
- |
- |
| Invested Capital |
-8.05 |
-1.26 |
-0.12 |
| Increase / (Decrease) in Invested Capital |
0.00 |
6.79 |
1.14 |
| Book Value per Share |
$0.09 |
$0.98 |
$2.30 |
| Tangible Book Value per Share |
$0.09 |
$0.98 |
$2.30 |
| Total Capital |
11 |
32 |
80 |
| Total Debt |
10 |
0.00 |
0.00 |
| Total Long-Term Debt |
0.00 |
0.00 |
0.00 |
| Net Debt |
-8.94 |
-33 |
-81 |
| Capital Expenditures (CapEx) |
0.07 |
0.08 |
0.59 |
| Debt-free, Cash-free Net Working Capital (DFCFNWC) |
-3.51 |
-1.77 |
-1.09 |
| Debt-free Net Working Capital (DFNWC) |
16 |
31 |
79 |
| Net Working Capital (NWC) |
5.43 |
31 |
79 |
| Net Nonoperating Expense (NNE) |
9.47 |
6.84 |
12 |
| Net Nonoperating Obligations (NNO) |
-8.94 |
-33 |
-81 |
| Total Depreciation and Amortization (D&A) |
0.16 |
0.17 |
0.24 |
| Earnings Adjustments |
- |
- |
- |
| Adjusted Basic Earnings per Share |
$0.00 |
($0.76) |
($1.03) |
| Adjusted Weighted Average Basic Shares Outstanding |
0.00 |
33.93M |
39.96M |
| Adjusted Diluted Earnings per Share |
$0.00 |
($0.76) |
($1.03) |
| Adjusted Weighted Average Diluted Shares Outstanding |
0.00 |
33.93M |
39.96M |
| Adjusted Basic & Diluted Earnings per Share |
$0.00 |
$0.00 |
$0.00 |
| Adjusted Weighted Average Basic & Diluted Shares Outstanding |
0.00 |
35.64M |
60.29M |
| Normalized Net Operating Profit after Tax (NOPAT) |
-19 |
-19 |
-27 |
| Debt Service Ratios |
- |
- |
- |
| Payout Ratios |
- |
- |
- |
Quarterly Metrics And Ratios for Eupraxia Pharmaceuticals
No quarterly metrics and ratios for Eupraxia Pharmaceuticals are available.
